Americana Partners LLC Makes New $590,000 Investment in Catalent, Inc. (NYSE:CTLT)

Americana Partners LLC acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the third quarter, Holdings Channel.com reports. The firm acquired 9,736 shares of the company’s stock, valued at approximately $590,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norden Group LLC bought a new stake in shares of Catalent during the 1st quarter worth approximately $1,222,000. Commonwealth Equity Services LLC purchased a new stake in shares of Catalent during the first quarter valued at $1,736,000. Diversify Advisory Services LLC purchased a new stake in shares of Catalent during the first quarter valued at $1,040,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Catalent by 33.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company’s stock worth $1,230,000 after purchasing an additional 5,499 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Catalent by 154.6% in the 1st quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company’s stock worth $12,211,000 after buying an additional 131,360 shares during the period.

Insider Transactions at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.2 %

Shares of NYSE CTLT opened at $58.73 on Friday. The stock has a market capitalization of $10.66 billion, a PE ratio of -10.70, a price-to-earnings-growth ratio of 2.07 and a beta of 1.15. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 12-month low of $32.38 and a 12-month high of $61.20. The stock’s fifty day simple moving average is $60.07 and its two-hundred day simple moving average is $57.93.

Catalent (NYSE:CTLT) last posted its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. As a group, analysts expect that Catalent, Inc. will post 0.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. StockNews.com started coverage on shares of Catalent in a research report on Saturday, October 12th. They issued a “hold” rating for the company. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Nine research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.